Rates and hazard ratios for first serious infection comparing sarcoidosis to the general population in sensitivity analyses
| Individuals at risk | Events | Adjusted rate per 1000 person-years# (95% CI) | Hazard ratio# (95% CI) | Adjusted hazard ratio# (95% CI) | |
| Hospitalisation and ≥1 dispensation of an antimicrobial ±15 days from hospital admission¶ | |||||
| Sarcoidosis | 6723 | 427 | 14.7 (13.0–16.6) | 2.82 (2.53–3.14) | 2.23 (1.96–2.54) |
| General population | 66 441 | 1562 | 6.6 (6.3–6.9) | 1.00 (Referent) | 1.00 (Referent) |
| Excluding pneumonias from serious infection definition | |||||
| Sarcoidosis | 8737 | 694 | 13.1 (11.9–14.4) | 2.32 (2.14–2.52) | 1.72 (1.56–1.90) |
| General population | 86 376 | 3088 | 7.6 (7.3–7.9) | 1.00 (Referent) | 1.00 (Referent) |
| Excluding urinary tract infections from serious infection definition | |||||
| Sarcoidosis | 8737 | 866 | 16.8 (15.4–18.3) | 2.51 (2.33–2.70) | 1.89 (1.72–2.07) |
| General population | 86 376 | 3600 | 8.9 (8.6–9.2) | 1.00 (Referent) | 1.00 (Referent) |
| Requiring comparators to have ≥1 healthcare visit in the NPR within 2 years before first visit for sarcoidosis or corresponding date in comparators | |||||
| Sarcoidosis, overall | 8737 | 895 | 17.4 (16.0–18.9) | 1.59 (1.48–1.72) | 1.23 (1.12–1.35) |
| General population | 42 406 | 2704 | 14.2 (13.6–14.7) | 1.00 (Referent) | 1.00 (Referent) |
| Sarcoidosis, treated¶ | 2762 | 326 | 29.8 (25.9–34.3) | 2.45 (2.15–2.80) | 2.08 (1.77–2.43) |
| General population¶ | 13 852 | 696 | 14.4 (13.3–15.5) | 1.00 (Referent) | 1.00 (Referent) |
| Sarcoidosis, not treated¶ | 3961 | 275 | 15.7 (13.5–18.3) | 1.28 (1.12–1.46) | 1.03 (0.88–1.22) |
| General population¶ | 19 802 | 1054 | 15.2 (14.3–16.2) | 1.00 (Referent) | 1.00 (Referent) |
| Excluding individuals with a serious infection within a year before first visit for sarcoidosis or corresponding date in comparators | |||||
| Sarcoidosis | 8396 | 802 | 16.3 (15.0–17.9) | 2.30 (2.13–2.49) | 1.77 (1.61–1.95) |
| General population | 85 678 | 3716 | 9.2 (8.9–9.5) | 1.00 (Referent) | 1.00 (Referent) |
| In Karolinska clinical cohort | |||||
| Sarcoidosis | 693 | 47 | 11.1 (7.8–15.9) | 1.80 (1.32–2.46) | 1.49 (1.02–2.18) |
| General population | 6867 | 261 | 7.4 (6.6–8.4) | 1.00 (Referent) | 1.00 (Referent) |
Data are presented as n, unless otherwise stated. NPR: National Patient Register. #: adjusted rates and adjusted hazard ratios were estimated using Poisson or Cox regression models weighted for inverse probability of sarcoidosis weights and years of follow-up as the time scale. Hazard ratios obtained from a cohort matched on age, sex and residential location; ¶: ascertained in individuals included starting January 1, 2006 for whom medication dispensations could be obtained from the Prescribed Drug Register.